TR202013232A2 - Eltrombopag kolin içeren katı oral kompozisyon - Google Patents

Eltrombopag kolin içeren katı oral kompozisyon

Info

Publication number: TR202013232A2
Authority: TR; Turkey
Prior art keywords: solid oral; oral composition; sodium; composition according; less
Prior art date: 2020-08-21

Application number

TR2020/13232A

Other languages

English (en)

Turkish (tr)

Inventor

Sünel Fati̇h

Tok Gülçi̇n

Demi̇r Bülent

Köksal Uzun Seli̇n

Sermet Başaran Sali̇h

Original Assignee

Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-08-21

Filing date

2020-08-21

Publication date

2022-03-21

2020-08-21 Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi

2020-08-21 Priority to TR2020/13232A priority Critical patent/TR202013232A2/tr

2021-08-13 Priority to PCT/TR2021/050799 priority patent/WO2022039701A1/en

2021-08-13 Priority to EP21858732.7A priority patent/EP4199921A4/de

2022-03-21 Publication of TR202013232A2 publication Critical patent/TR202013232A2/tr

Links

239000000203 mixture Substances 0.000 title claims abstract description 84
239000007787 solid Substances 0.000 title claims abstract description 41
XDXWLKQMMKQXPV-QYQHSDTDSA-N eltrombopag Chemical compound CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 XDXWLKQMMKQXPV-QYQHSDTDSA-N 0.000 title claims abstract description 38
229960001069 eltrombopag Drugs 0.000 title claims abstract description 37
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 title claims description 25
229960001231 choline Drugs 0.000 title claims description 25
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
238000000034 method Methods 0.000 claims abstract description 7
239000003826 tablet Substances 0.000 claims description 18
238000009472 formulation Methods 0.000 claims description 16
239000011230 binding agent Substances 0.000 claims description 12
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
239000003085 diluting agent Substances 0.000 claims description 9
239000007884 disintegrant Substances 0.000 claims description 9
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
229930195725 Mannitol Natural products 0.000 claims description 8
235000010443 alginic acid Nutrition 0.000 claims description 8
229920000615 alginic acid Polymers 0.000 claims description 8
239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
239000000594 mannitol Substances 0.000 claims description 8
235000010355 mannitol Nutrition 0.000 claims description 8
206010043554 thrombocytopenia Diseases 0.000 claims description 8
239000002775 capsule Substances 0.000 claims description 7
239000002245 particle Substances 0.000 claims description 7
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 6
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
239000008108 microcrystalline cellulose Substances 0.000 claims description 6
229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
229920002785 Croscarmellose sodium Polymers 0.000 claims description 5
239000002202 Polyethylene glycol Substances 0.000 claims description 5
229960001681 croscarmellose sodium Drugs 0.000 claims description 5
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 5
239000008187 granular material Substances 0.000 claims description 5
229920001223 polyethylene glycol Polymers 0.000 claims description 5
239000000843 powder Substances 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
229920003109 sodium starch glycolate Polymers 0.000 claims description 5
239000008109 sodium starch glycolate Substances 0.000 claims description 5
229940079832 sodium starch glycolate Drugs 0.000 claims description 5
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
108010010803 Gelatin Proteins 0.000 claims description 4
229920002907 Guar gum Polymers 0.000 claims description 4
239000005913 Maltodextrin Substances 0.000 claims description 4
229920002774 Maltodextrin Polymers 0.000 claims description 4
229920000881 Modified starch Polymers 0.000 claims description 4
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
229920002125 Sokalan® Polymers 0.000 claims description 4
229920002472 Starch Polymers 0.000 claims description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
229930006000 Sucrose Natural products 0.000 claims description 4
239000000783 alginic acid Substances 0.000 claims description 4
229960001126 alginic acid Drugs 0.000 claims description 4
150000004781 alginic acids Chemical class 0.000 claims description 4
229960001631 carbomer Drugs 0.000 claims description 4
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
229940105329 carboxymethylcellulose Drugs 0.000 claims description 4
229920000159 gelatin Polymers 0.000 claims description 4
239000008273 gelatin Substances 0.000 claims description 4
229940014259 gelatin Drugs 0.000 claims description 4
235000019322 gelatine Nutrition 0.000 claims description 4
235000011852 gelatine desserts Nutrition 0.000 claims description 4
235000010417 guar gum Nutrition 0.000 claims description 4
239000000665 guar gum Substances 0.000 claims description 4
229960002154 guar gum Drugs 0.000 claims description 4
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
229940035034 maltodextrin Drugs 0.000 claims description 4
229960000502 poloxamer Drugs 0.000 claims description 4
229920001983 poloxamer Polymers 0.000 claims description 4
229920001282 polysaccharide Polymers 0.000 claims description 4
239000005017 polysaccharide Substances 0.000 claims description 4
150000004804 polysaccharides Chemical class 0.000 claims description 4
235000010413 sodium alginate Nutrition 0.000 claims description 4
239000000661 sodium alginate Substances 0.000 claims description 4
229940005550 sodium alginate Drugs 0.000 claims description 4
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
239000008107 starch Substances 0.000 claims description 4
229940032147 starch Drugs 0.000 claims description 4
235000019698 starch Nutrition 0.000 claims description 4
239000005720 sucrose Substances 0.000 claims description 4
229920002261 Corn starch Polymers 0.000 claims description 3
229920001100 Polydextrose Polymers 0.000 claims description 3
239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
239000001913 cellulose Substances 0.000 claims description 3
239000008120 corn starch Substances 0.000 claims description 3
239000007937 lozenge Substances 0.000 claims description 3
235000013856 polydextrose Nutrition 0.000 claims description 3
239000001259 polydextrose Substances 0.000 claims description 3
229940035035 polydextrose Drugs 0.000 claims description 3
229920000193 polymethacrylate Polymers 0.000 claims description 3
229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
229940068984 polyvinyl alcohol Drugs 0.000 claims description 3
229960004793 sucrose Drugs 0.000 claims description 3
238000005550 wet granulation Methods 0.000 claims description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
235000019739 Dicalciumphosphate Nutrition 0.000 claims description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
229940072056 alginate Drugs 0.000 claims description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
239000011324 bead Substances 0.000 claims description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
239000011575 calcium Substances 0.000 claims description 2
229910052791 calcium Inorganic materials 0.000 claims description 2
235000001465 calcium Nutrition 0.000 claims description 2
239000001506 calcium phosphate Substances 0.000 claims description 2
235000010418 carrageenan Nutrition 0.000 claims description 2
239000000679 carrageenan Substances 0.000 claims description 2
229920001525 carrageenan Polymers 0.000 claims description 2
229940113118 carrageenan Drugs 0.000 claims description 2
229940099112 cornstarch Drugs 0.000 claims description 2
229960000913 crospovidone Drugs 0.000 claims description 2
229940096516 dextrates Drugs 0.000 claims description 2
239000008121 dextrose Substances 0.000 claims description 2
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 2
229940038472 dicalcium phosphate Drugs 0.000 claims description 2
229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 2
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 claims description 2
229960000878 docusate sodium Drugs 0.000 claims description 2
239000008298 dragée Substances 0.000 claims description 2
239000000945 filler Substances 0.000 claims description 2
239000010408 film Substances 0.000 claims description 2
229920002674 hyaluronan Polymers 0.000 claims description 2
229960003160 hyaluronic acid Drugs 0.000 claims description 2
239000003456 ion exchange resin Substances 0.000 claims description 2
229920003303 ion-exchange polymer Polymers 0.000 claims description 2
239000000832 lactitol Substances 0.000 claims description 2
235000010448 lactitol Nutrition 0.000 claims description 2
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
229960003451 lactitol Drugs 0.000 claims description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
239000004005 microsphere Substances 0.000 claims description 2
229920001206 natural gum Polymers 0.000 claims description 2
229920001277 pectin Polymers 0.000 claims description 2
235000010987 pectin Nutrition 0.000 claims description 2
239000001814 pectin Substances 0.000 claims description 2
229960000292 pectin Drugs 0.000 claims description 2
239000006187 pill Substances 0.000 claims description 2
229920002401 polyacrylamide Polymers 0.000 claims description 2
229920000642 polymer Polymers 0.000 claims description 2
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
239000011591 potassium Substances 0.000 claims description 2
229910052700 potassium Inorganic materials 0.000 claims description 2
229960003975 potassium Drugs 0.000 claims description 2
235000007686 potassium Nutrition 0.000 claims description 2
229920003124 powdered cellulose Polymers 0.000 claims description 2
235000019814 powdered cellulose Nutrition 0.000 claims description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
239000011780 sodium chloride Substances 0.000 claims description 2
229960002668 sodium chloride Drugs 0.000 claims description 2
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 2
239000000600 sorbitol Substances 0.000 claims description 2
235000000346 sugar Nutrition 0.000 claims description 2
229920001285 xanthan gum Polymers 0.000 claims description 2
235000010493 xanthan gum Nutrition 0.000 claims description 2
239000000230 xanthan gum Substances 0.000 claims description 2
229940082509 xanthan gum Drugs 0.000 claims description 2
239000000811 xylitol Substances 0.000 claims description 2
235000010447 xylitol Nutrition 0.000 claims description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
229960002675 xylitol Drugs 0.000 claims description 2
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
235000019264 food flavour enhancer Nutrition 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
230000008569 process Effects 0.000 abstract description 4
238000004090 dissolution Methods 0.000 description 10
102000036693 Thrombopoietin Human genes 0.000 description 7
108010041111 Thrombopoietin Proteins 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
229940075614 colloidal silicon dioxide Drugs 0.000 description 6
229960001855 mannitol Drugs 0.000 description 6
239000000126 substance Substances 0.000 description 6
102100034196 Thrombopoietin receptor Human genes 0.000 description 5
239000011248 coating agent Substances 0.000 description 5
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 5
-1 olamine Chemical class 0.000 description 5
229940045902 sodium stearyl fumarate Drugs 0.000 description 5
239000013543 active substance Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000008188 pellet Substances 0.000 description 4
210000001772 blood platelet Anatomy 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
DJMJHIKGMVJYCW-UHFFFAOYSA-N 2-aminoethanol 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid Chemical compound CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C.C(CO)N.C(CO)N DJMJHIKGMVJYCW-UHFFFAOYSA-N 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
239000004349 Polyvinylpyrrolidone-vinyl acetate copolymer Substances 0.000 description 2
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
229940127323 Thrombopoietin Receptor Agonists Drugs 0.000 description 2
108010070774 Thrombopoietin Receptors Proteins 0.000 description 2
101710148535 Thrombopoietin receptor Proteins 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000011162 core material Substances 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000002502 liposome Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000003593 megakaryocyte Anatomy 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
239000008185 minitablet Substances 0.000 description 2
235000019448 polyvinylpyrrolidone-vinyl acetate copolymer Nutrition 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Polymers OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
SVOQIEJWJCQGDQ-UHFFFAOYSA-N 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid Chemical group CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C SVOQIEJWJCQGDQ-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
PLILLUUXAVKBPY-SBIAVEDLSA-N NCCO.NCCO.CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 Chemical compound NCCO.NCCO.CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 PLILLUUXAVKBPY-SBIAVEDLSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
101150116986 THPO gene Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229920001531 copovidone Polymers 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000007919 dispersible tablet Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
229960001827 eltrombopag olamine Drugs 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
238000012395 formulation development Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000009474 hot melt extrusion Methods 0.000 description 1
239000012943 hotmelt Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229940071676 hydroxypropylcellulose Drugs 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
238000007561 laser diffraction method Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
230000035800 maturation Effects 0.000 description 1
229940057917 medium chain triglycerides Drugs 0.000 description 1
238000007909 melt granulation Methods 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000007912 modified release tablet Substances 0.000 description 1
229950004864 olamine Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229940021945 promacta Drugs 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
238000009491 slugging Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000003582 thrombocytopenic effect Effects 0.000 description 1
229940126460 thrombopoietin receptor agonist Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001238 wet grinding Methods 0.000 description 1
229940045860 white wax Drugs 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TR2020/13232A 2020-08-21 2020-08-21 Eltrombopag kolin içeren katı oral kompozisyon TR202013232A2 (tr)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
TR2020/13232A TR202013232A2 (tr)	2020-08-21	2020-08-21	Eltrombopag kolin içeren katı oral kompozisyon
PCT/TR2021/050799 WO2022039701A1 (en)	2020-08-21	2021-08-13	A solid oral composition comprising eltrombopag choline
EP21858732.7A EP4199921A4 (de)	2020-08-21	2021-08-13	Feste orale zusammensetzung mit eltrombopag-cholin

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
TR2020/13232A TR202013232A2 (tr)	2020-08-21	2020-08-21	Eltrombopag kolin içeren katı oral kompozisyon

Publications (1)

Publication Number	Publication Date
TR202013232A2 true TR202013232A2 (tr)	2022-03-21

Family

ID=80323655

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TR2020/13232A TR202013232A2 (tr)	2020-08-21	2020-08-21	Eltrombopag kolin içeren katı oral kompozisyon

Country Status (3)

Country	Link
EP (1)	EP4199921A4 (de)
TR (1)	TR202013232A2 (de)
WO (1)	WO2022039701A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN117281780B (zh) *	2023-11-24	2024-02-02	山东则正医药技术有限公司	一种艾曲泊帕乙醇胺干混悬剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017042839A1 (en) *	2015-09-08	2017-03-16	Actavis Group Ptc Ehf.	Novel eltrombopag salt and preparation thereof
WO2018078644A1 (en) *	2016-10-24	2018-05-03	Hetero Labs Limited	Orally disintegrating tablets of eltrombopag
WO2019071111A1 (en) *	2017-10-06	2019-04-11	Teva Pharmaceuticals Usa, Inc.	FORMS IN THE STRONG STATE OF ELTROMBOPAG CHOLINE
EP3409272B1 (de) *	2018-03-07	2020-06-24	Alfred E. Tiefenbacher (GmbH & Co. KG)	Pharmazeutische zusammensetzung mit eltrombopag olamin, reduzierendem zucker und polymerem bindemittel
WO2020055364A2 (en) *	2018-08-02	2020-03-19	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A pharmaceutical composition comprising eltrombopag olamine

2020
- 2020-08-21 TR TR2020/13232A patent/TR202013232A2/tr unknown
2021
- 2021-08-13 EP EP21858732.7A patent/EP4199921A4/de not_active Withdrawn
- 2021-08-13 WO PCT/TR2021/050799 patent/WO2022039701A1/en not_active Ceased

Also Published As

Publication number	Publication date
EP4199921A4 (de)	2024-09-25
WO2022039701A1 (en)	2022-02-24
EP4199921A1 (de)	2023-06-28

Publication	Publication Date	Title
CA2499878C (en)	2012-03-13	Solid pharmaceutical formulations comprising telmisartan
KR101600099B1 (ko)	2016-03-04	매트릭스형 의약 고형 제제
HU196304B (en)	1988-11-28	Process for production of granulates of medical active substances with delaying effect
US8980870B2 (en)	2015-03-17	Solid telmisartan pharmaceutical formulations
CZ2002671A3 (cs)	2002-06-12	Léková forma se zpoľděným účinkem obsahující tramadolsacharinát
SK3722001A3 (en)	2001-10-08	Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
CA3104695A1 (en)	2020-02-20	Formulations of ag10
JP5490347B2 (ja)	2014-05-14	経口投与用製剤
CN104254321A (zh)	2014-12-31	稳定性提高的药物制剂
TR202013232A2 (tr)	2022-03-21	Eltrombopag kolin içeren katı oral kompozisyon
TR202014694A1 (tr)	2022-03-21	Eltrombopag olami̇n i̇çeren bi̇r kati oral farmasöri̇k formülasyon
US20100310652A1 (en)	2010-12-09	Coated extended release pharmaceutical compositions of levetiracetam
US20080081069A1 (en)	2008-04-03	Novel controlled release formulations of divalproex sodium
JP7761403B2 (ja)	2025-10-28	水不溶性ポリマーコーティング顆粒、それを含む製剤、口腔内崩壊錠及びそれらの製造方法
TR201802243T4 (tr)	2018-03-21	Vildagliptin ve gliklazid kombinasyon kompozisyonu.
WO2025170558A1 (en)	2025-08-14	A solid oral pharmaceutical formulation comprising avatrombopag
US20130209553A1 (en)	2013-08-15	Extended release pharmaceutical compositions of pramipexole
EP3796899B1 (de)	2023-08-30	Neuartige pharmazeutische zusammensetzung von tamsulosin und dutasterid
EP4599824A1 (de)	2025-08-13	Feste orale pharmazeutische formulierung mit avatrombopag
TR201703066A2 (tr)	2018-09-21	İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
KR102488167B1 (ko)	2023-01-12	피롤카르복사미드의 고형 조성물
TR201906487A1 (tr)	2020-11-23	Tolperi̇zon ve ni̇mesuli̇d kombi̇nasyonlari i̇çeren farmasöti̇k kompozi̇syonlar
Menéndez	2003	A novel approach for the manufacturing of extended-release pellets
HK1144775B (en)	2013-08-30	Matrix-type pharmaceutical solid preparation
CZ2001227A3 (cs)	2001-07-11	Biologicky zlepšené prostředky obsahující eprosartan v orální pevné dávkové formě